{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:02:41Z","timestamp":1791478961340,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1124\/dmd.114.059576","type":"journal-article","created":{"date-parts":[[2014,9,27]],"date-time":"2014-09-27T03:29:23Z","timestamp":1411788563000},"page":"2068-2076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Paroxetine Markedly Increases Plasma Concentrations of Ophthalmic Timolol; CYP2D6 Inhibitors May Increase the Risk of Cardiovascular Adverse Effects of 0.5% Timolol Eye Drops"],"prefix":"10.1016","volume":"42","author":[{"given":"Jukka","family":"M\u00e4enp\u00e4\u00e4","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjo","family":"Volotinen-Maja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannu","family":"Kautiainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Neuvonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Niemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pertti J.","family":"Neuvonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne T.","family":"Backman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.114.059576_bib1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(82)91583-5","article-title":"High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation","volume":"1","author":"Alvan","year":"1982","journal-title":"Lancet"},{"key":"10.1124\/dmd.114.059576_bib2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1124\/dmd.31.3.289","article-title":"Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine","volume":"31","author":"Bertelsen","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.059576_bib3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2165\/00002512-199202030-00005","article-title":"Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects","volume":"2","author":"Brooks","year":"1992","journal-title":"Drugs Aging"},{"key":"10.1124\/dmd.114.059576_bib4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00316471","article-title":"Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine","volume":"44","author":"Br\u00f8sen","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.114.059576_bib5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3129\/can j ophthalmol.06-111","article-title":"Sinoatrial block induced by timolol eyedrops","volume":"42","author":"Calenda","year":"2007","journal-title":"Can J Ophthalmol"},{"key":"10.1124\/dmd.114.059576_bib6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00059-012-3725-7","article-title":"Severe bradycardia and syncope due to topical ophthalmic timolol","volume":"38","author":"Canpolat","year":"2013","journal-title":"Herz"},{"key":"10.1124\/dmd.114.059576_bib7","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/ageing\/afl031","article-title":"Atishoo! Atishoo! we all fall down!","volume":"35","author":"Carey","year":"2006","journal-title":"Age Ageing"},{"key":"10.1124\/dmd.114.059576_bib8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.chroma.2007.06.014","article-title":"Analysis of paroxetine, fluoxetine and norfluoxetine in fish tissues using pressurized liquid extraction, mixed mode solid phase extraction cleanup and liquid chromatography-tandem mass spectrometry","volume":"1163","author":"Chu","year":"2007","journal-title":"J Chromatogr A"},{"key":"10.1124\/dmd.114.059576_bib9","doi-asserted-by":"crossref","first-page":"890","DOI":"10.7326\/0003-4819-103-6-890","article-title":"Bradycardia induced by interaction between quinidine and ophthalmic timolol","volume":"103","author":"Dinai","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1124\/dmd.114.059576_bib10","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1001\/jama.1995.03530200047035","article-title":"Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction","volume":"274","author":"Edeki","year":"1995","journal-title":"JAMA"},{"key":"10.1124\/dmd.114.059576_bib11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00561948","article-title":"Pharmacokinetics of oral timolol studied by mass fragmentography","volume":"19","author":"Fourtillan","year":"1981","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.114.059576_bib12","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00132580-200111000-00007","article-title":"Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus on beta-adrenergic blockade","volume":"3","author":"Frishman","year":"2001","journal-title":"Heart Dis"},{"key":"10.1124\/dmd.114.059576_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/archopht.1991.01080020051041","article-title":"Falls in elderly patients with glaucoma","volume":"109","author":"Glynn","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"10.1124\/dmd.114.059576_bib14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1067\/mcp.2000.104788","article-title":"Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"67","author":"Hemeryck","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.059576_bib15","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/archopht.1996.01100130737019","article-title":"Topical beta-adrenergic antagonists and quinidine. A risky interaction","volume":"114","author":"Higginbotham","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1124\/dmd.114.059576_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40266-012-0036-x","article-title":"Ophthalmic drugs as part of polypharmacy in nursing home residents with glaucoma","volume":"30","author":"Huber","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1124\/dmd.114.059576_bib17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/00912700022008739","article-title":"Drug interaction between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers","volume":"40","author":"Ishii","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.114.059576_bib18","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(05)67604-0","article-title":"Prevention of falls and consequent injuries in elderly people","volume":"366","author":"Kannus","year":"2005","journal-title":"Lancet"},{"key":"10.1124\/dmd.114.059576_bib19","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s00417-002-0462-2","article-title":"Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops","volume":"240","author":"Korte","year":"2002","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1124\/dmd.114.059576_bib20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2125.1985.tb02651.x","article-title":"Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics","volume":"19","author":"Lewis","year":"1985","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.114.059576_bib21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0009-9236(99)70129-3","article-title":"Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists","volume":"65","author":"Mart\u00ednez","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.059576_bib22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/clpt.1985.195","article-title":"Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin","volume":"38","author":"McGourty","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.059576_bib23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0736-4679(01)00476-0","article-title":"Symptomatic bradycardia secondary to interaction between topical timolol maleate, verapamil, and flecainide: a case report","volume":"22","author":"Minish","year":"2002","journal-title":"J Emerg Med"},{"key":"10.1124\/dmd.114.059576_bib24","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/bmj.332.7547.960","article-title":"Syncope and falls due to timolol eye drops","volume":"332","author":"M\u00fcller","year":"2006","journal-title":"BMJ"},{"key":"10.1124\/dmd.114.059576_bib25","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/0002-9394(86)90532-5","article-title":"Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985","volume":"102","author":"Nelson","year":"1986","journal-title":"Am J Ophthalmol"},{"key":"10.1124\/dmd.114.059576_bib26","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00228-010-0803-8","article-title":"Two separate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadol\u2019s O-demethylation via CYP2D6","volume":"66","author":"Nielsen","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.114.059576_bib27","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00228-005-0052-4","article-title":"Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study","volume":"61","author":"Nieminen","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.114.059576_bib28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00228-005-0945-2","article-title":"Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients","volume":"61","author":"Nieminen","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.114.059576_bib29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1475-097X.2002.00430.x","article-title":"Cardiovascular effects of ophthalmic 0.5% timolol aqueous solution and 0.1% timolol hydrogel","volume":"22","author":"Ni\u00f1o","year":"2002","journal-title":"Clin Physiol Funct Imaging"},{"key":"10.1124\/dmd.114.059576_bib31","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.ijcard.2007.01.017","article-title":"Atrial fibrillation, pharmacological cardioversion and topical ophthalmic beta-blocker use","volume":"126","author":"Patane\u2019","year":"2008","journal-title":"Int J Cardiol"},{"key":"10.1124\/dmd.114.059576_bib32","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(10)61423-7","article-title":"Glaucoma","volume":"377","author":"Quigley","year":"2011","journal-title":"Lancet"},{"key":"10.1124\/dmd.114.059576_bib33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000067548","article-title":"Timolol 0.1% gel (Nyogel 0.1%) once daily versus conventional timolol 0.5% solution twice daily: a comparison of efficacy and safety","volume":"216","author":"Rouland","year":"2002","journal-title":"Ophthalmologica"},{"key":"10.1124\/dmd.114.059576_bib34","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00228-004-0792-6","article-title":"Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine","volume":"60","author":"Sawamura","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.114.059576_bib35","doi-asserted-by":"crossref","first-page":"406","DOI":"10.5694\/j.1326-5377.2008.tb02092.x","article-title":"A case of melancholic depression induced by beta-blocker antiglaucoma agents","volume":"189","author":"Schweitzer","year":"2008","journal-title":"Med J Aust"},{"key":"10.1124\/dmd.114.059576_bib36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0039-6257(82)90081-9","article-title":"Pharmacokinetics of topically applied ophthalmic drugs","volume":"26","author":"Shell","year":"1982","journal-title":"Surv Ophthalmol"},{"key":"10.1124\/dmd.114.059576_bib37","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1373\/clinchem.2004.046466","article-title":"CYP2D6 genotyping by a multiplex primer extension reaction","volume":"51","author":"Sistonen","year":"2005","journal-title":"Clin Chem"},{"key":"10.1124\/dmd.114.059576_bib38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00055735-199704000-00010","article-title":"The potential systemic effect of topically applied beta-blockers in glaucoma therapy","volume":"8","author":"Taniguchi","year":"1997","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1124\/dmd.114.059576_bib39","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00417-006-0328-0","article-title":"Improved systemic safety and risk-benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma","volume":"244","author":"Uusitalo","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1124\/dmd.114.059576_bib40","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1600-0420.2005.00562.x","article-title":"Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel","volume":"83","author":"Uusitalo","year":"2005","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1124\/dmd.114.059576_bib41","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0161-6420(80)35215-9","article-title":"Adverse reactions from timolol administration","volume":"87","author":"Van Buskirk","year":"1980","journal-title":"Ophthalmology"},{"key":"10.1124\/dmd.114.059576_bib42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/0002-9394(84)90250-2","article-title":"Ocular beta-blockers and systemic effects","volume":"98","author":"Van Buskirk","year":"1984","journal-title":"Am J Ophthalmol"},{"key":"10.1124\/dmd.114.059576_bib43","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/gerona\/59.12.1343","article-title":"Falls in three patients due to timolol eye drops, tolterodine, and flecainide","volume":"59","author":"van der Velde","year":"2004","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1124\/dmd.114.059576_bib44","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1742-7843.2011.00694.x","article-title":"Metabolism of ophthalmic timolol: new aspects of an old drug","volume":"108","author":"Volotinen","year":"2011","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/dmd.114.059576_bib45","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1742-7843.2009.00487.x","article-title":"Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes","volume":"106","author":"Volotinen","year":"2010","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/dmd.114.059576_bib46","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1124\/dmd.106.012906","article-title":"Timolol metabolism in human liver microsomes is mediated principally by CYP2D6","volume":"35","author":"Volotinen","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.059576_bib47","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4103\/0976-500X.85946","article-title":"Sick sinus syndrome associated with topical timolol maleate instillation","volume":"2","author":"Walia","year":"2011","journal-title":"J Pharmacol Pharmacother"},{"key":"10.1124\/dmd.114.059576_bib48","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1021\/jm00185a006","article-title":"Urinary metabolites of timolol from humans and laboratory animals. Syntheses and beta-adrenergic blocking activities","volume":"23","author":"Wasson","year":"1980","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.114.059576_bib49","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/clpt.1982.223","article-title":"Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade","volume":"32","author":"Wilson","year":"1982","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.059576_bib50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00210-003-0832-2","article-title":"Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry","volume":"369","author":"Zanger","year":"2004","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624114912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624114912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.114.059576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:37:08Z","timestamp":1739907428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624114912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0090955624114912"],"URL":"https:\/\/doi.org\/10.1124\/dmd.114.059576","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paroxetine Markedly Increases Plasma Concentrations of Ophthalmic Timolol; CYP2D6 Inhibitors May Increase the Risk of Cardiovascular Adverse Effects of 0.5% Timolol Eye Drops","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.114.059576","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}